JohnLazarchickMD

Hematopathology, Clinical Pathology

Professor, Pathology, Medical University of South Carolina College of Medicine

Are you Dr. Lazarchick?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 66 invites waiting!
Read the latest clinical news, personalized to your specialty.

Dr. John Lazarchick, MD is a board certified pathologist in Charleston, South Carolina. He is currently licensed to practice medicine in South Carolina. He is affiliated with MUSC Health University Medical Center and Roper Hospital.

Naval Regional Medical CenterFellowship, Hematopathology, 1973 - 1974
Massachusetts General HospitalResidency, Internal Medicine, 1971 - 1972
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1969 - 1971
University of Southern California/LACUSC Medical CenterInternship, Transitional Year, 1968 - 1969
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1968

PubMed

A Novel Case of Compound Heterozygous Type 3 Von Willebrand Disease.
Mamatha Mandava, Shayla Bergmann, John Lazarchick
Annals of Clinical and Laboratory Science. 2019-05-01
14 citations
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Jing Zheng, Yonggang Sha, Logan Roof, Oded Foreman, John Lazarchick
Cancer Letters. 2019-01-01
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Jing Zheng, Jing Zheng, Jing Zheng, Yonggang Sha, Yonggang Sha
Cancer letters. 2018-10-13